RxDoctor Payments Data

Keino Rutherford, MD

Internal Medicine · Sherman Oaks, CANPI 1497807853

Payments from drug & device makers

$164in general payments, 2019–2025

Across 6 payments — averaging $27.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$73
  • Otsuka America Pharmaceutical, Inc.$49
  • Mylan Specialty L.p.$26
  • Avanir Pharmaceuticals, Inc.$16

What the payments were for

  • Food & beverage$164100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$164 in reported general payments places this provider in the 50th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$2,690,878
Medicare patients
1,693
Services billed
25,871

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate31$209,683
EliquisApixaban557$170,556
Invega SustennaPaliperidone Palmitate44$129,403
NuplazidPimavanserin Tartrate41$114,190
Combivent RespimatIpratropium/Albuterol Sulfate133$69,705
XifaxanRifaximin43$60,407
Austedo XrDeutetrabenazine13$59,958
EntrestoSacubitril/Valsartan162$54,750
OtezlaApremilast22$53,605
TradjentaLinagliptin146$41,909
SantylCollagenase Clostridium Hist.55$41,587
Divalproex Sodium889$40,817
XareltoRivaroxaban127$36,320
JardianceEmpagliflozin109$36,170
JanuviaSitagliptin Phosphate88$30,713

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$73$209,68331 claims
Otsuka America Pharmaceutical, Inc.Rexulti$49$7,90215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Sherman Oaks

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →